JP7190513B2 - ガレクチン－３抑制剤を模したテトラヒドロピラン系チオ二糖類 - Google Patents

ガレクチン－３抑制剤を模したテトラヒドロピラン系チオ二糖類 Download PDF

Info

Publication number
JP7190513B2
JP7190513B2 JP2020569778A JP2020569778A JP7190513B2 JP 7190513 B2 JP7190513 B2 JP 7190513B2 JP 2020569778 A JP2020569778 A JP 2020569778A JP 2020569778 A JP2020569778 A JP 2020569778A JP 7190513 B2 JP7190513 B2 JP 7190513B2
Authority
JP
Japan
Prior art keywords
pyran
mmol
tetrahydro
triazol
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020569778A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021527102A5 (https=
JP2021527102A (ja
JPWO2019241461A5 (https=
Inventor
リチャード・エイ・ハーツ
リ・シュー
デイビッド・エス・ユン
アリシア・レゲイロ－レン
プラサダ・ラオ・ジャラガム
マノランジャン・パンダ
サティーシュ・ケサバン・ナイル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2021527102A publication Critical patent/JP2021527102A/ja
Publication of JP2021527102A5 publication Critical patent/JP2021527102A5/ja
Publication of JPWO2019241461A5 publication Critical patent/JPWO2019241461A5/ja
Application granted granted Critical
Publication of JP7190513B2 publication Critical patent/JP7190513B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
JP2020569778A 2018-06-15 2019-06-13 ガレクチン－３抑制剤を模したテトラヒドロピラン系チオ二糖類 Active JP7190513B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862685395P 2018-06-15 2018-06-15
US62/685,395 2018-06-15
US201962831867P 2019-04-10 2019-04-10
US62/831,867 2019-04-10
PCT/US2019/036877 WO2019241461A1 (en) 2018-06-15 2019-06-13 Tetrahydropyran-based thiodisaccharide mimics as galectin-3 inhibitors

Publications (4)

Publication Number Publication Date
JP2021527102A JP2021527102A (ja) 2021-10-11
JP2021527102A5 JP2021527102A5 (https=) 2022-01-14
JPWO2019241461A5 JPWO2019241461A5 (https=) 2022-01-14
JP7190513B2 true JP7190513B2 (ja) 2022-12-15

Family

ID=67297250

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020569778A Active JP7190513B2 (ja) 2018-06-15 2019-06-13 ガレクチン－３抑制剤を模したテトラヒドロピラン系チオ二糖類

Country Status (7)

Country Link
US (1) US11970511B2 (https=)
EP (1) EP3807290B1 (https=)
JP (1) JP7190513B2 (https=)
KR (1) KR102802503B1 (https=)
CN (1) CN112292386B (https=)
ES (1) ES2912499T3 (https=)
WO (1) WO2019241461A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113366007A (zh) * 2018-10-15 2021-09-07 格莱克特生物技术公司 半乳糖凝集素的半乳糖苷抑制剂
JP2022508719A (ja) * 2018-10-15 2022-01-19 ガレクト バイオテック エービー ガレクチンのガラクトシド阻害剤のプロドラッグ
KR20230006547A (ko) * 2020-05-05 2023-01-10 브리스톨-마이어스 스큅 컴퍼니 갈렉틴-3의 소분자 억제제
EP4157833A1 (en) 2020-05-28 2023-04-05 Bristol-Myers Squibb Company Galectin-3 inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010126435A1 (en) 2009-04-28 2010-11-04 Forskarpatent I Syd Ab Novel galactoside inhibitors of galectins
JP2015535233A (ja) 2012-10-31 2015-12-10 ガレクト・バイオテック・エイビイ ガレクチン−３のガラクトシド阻害剤及び肺線維症のためのその使用
JP2017519756A (ja) 2014-07-09 2017-07-20 ガレクト バイオテック エービー ガレクチンの新規ハイブリッドガラクトシド阻害剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0401301D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
SE0401300D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel Galactoside Inhibitors of Galectins
US20140243302A1 (en) 2011-06-27 2014-08-28 Merck Sharp & Dohme Corporation Bridged bicyclic compounds for the treatment of bacterial infections
US9021050B2 (en) 2012-08-31 2015-04-28 Yume, Inc. Network service system and method with off-heap caching
US8828971B2 (en) 2012-10-10 2014-09-09 Galectin Therapeutics, Inc. Galactose-pronged carbohydrate compounds for the treatment of diabetic nephropathy and associated disorders
WO2014078655A1 (en) 2012-11-15 2014-05-22 Tufts University Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor
JP6904906B2 (ja) 2015-01-30 2021-07-21 ガレクト・バイオテック・エイビイ ガレクチンの新規なガラクトシド阻害剤
ES2921500T3 (es) 2015-11-09 2022-08-26 Galecto Biotech Ab 1,1'-sulfanodiil-di-beta-d-galactopiranósidos como inhibidores de galectinas
JP6844991B2 (ja) 2015-11-10 2021-03-17 サンコ テキスタイル イスレットメレリ サン ベ ティク エーエスＳａｎｋｏ Ｔｅｋｓｔｉｌ Ｉｓｌｅｔｍｅｌｅｒｉ Ｓａｎ． Ｖｅ Ｔｉｃ． Ａ．Ｓ． ジッパーを有する伸縮性衣類の製法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010126435A1 (en) 2009-04-28 2010-11-04 Forskarpatent I Syd Ab Novel galactoside inhibitors of galectins
JP2015535233A (ja) 2012-10-31 2015-12-10 ガレクト・バイオテック・エイビイ ガレクチン−３のガラクトシド阻害剤及び肺線維症のためのその使用
JP2017519756A (ja) 2014-07-09 2017-07-20 ガレクト バイオテック エービー ガレクチンの新規ハイブリッドガラクトシド阻害剤

Also Published As

Publication number Publication date
CN112292386B (zh) 2024-06-11
KR20210021015A (ko) 2021-02-24
EP3807290B1 (en) 2022-03-30
WO2019241461A1 (en) 2019-12-19
KR102802503B1 (ko) 2025-04-29
EP3807290A1 (en) 2021-04-21
CN112292386A (zh) 2021-01-29
US20210323991A1 (en) 2021-10-21
JP2021527102A (ja) 2021-10-11
US11970511B2 (en) 2024-04-30
ES2912499T3 (es) 2022-05-26

Similar Documents

Publication Publication Date Title
JP7190513B2 (ja) ガレクチン－３抑制剤を模したテトラヒドロピラン系チオ二糖類
CN104470925B (zh) 作为激酶抑制剂的咪唑并三嗪甲腈
CN114667167A (zh) 用于治疗癌症的杂环化合物
CN109641906B (zh) 杂芳基取代的氨基吡啶化合物
CN114615981A (zh) Kras g12d抑制剂
KR20210132666A (ko) Jak 억제제 화합물 및 그 사용
TW201609693A (zh) 雜芳基取代之菸鹼醯胺化合物
CN116670143A (zh) 囊性纤维化跨膜传导调控因子的调节剂
WO2019075045A1 (en) INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3
CN114591319A (zh) 四氢吡啶并嘧啶类衍生物及其用途
TWI739779B (zh) 布魯頓氏酪胺酸激酶抑制劑及其使用方法
CN105705501A (zh) RORγ调节剂
CN105492433A (zh) 6-(5-羟基-1h-吡唑-1-基)烟碱酰胺衍生物和其作为phd抑制剂的用途
CN112262139A (zh) 作为激酶抑制剂的氨基吡咯并三嗪
CN112566910A (zh) 用于治疗由IgE引起的疾病的噻吩衍生物
JP7478165B2 (ja) ガレクチン－３の低分子阻害剤
JP7705884B2 (ja) ガレクチン－３の低分子阻害剤
JP7772718B2 (ja) ガレクチン－３阻害剤
CN120981466A (zh) 作为egfr抑制剂的大环氨基吡啶化合物
HK40110644A (zh) 具有ent1抑制活性的大环化合物
EA050465B1 (ru) Соединения карбокси-бензимидазола, модулирующие glp-1r
HK40076948A (en) Kras g12d inhibitors
HK40076948B (zh) Kras g12d抑制剂
CN113166122A (zh) 半乳糖凝集素-3的小分子抑制剂
HK1196369B (en) Pyrrolopyrazine kinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220105

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221115

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221122

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221205

R150 Certificate of patent or registration of utility model

Ref document number: 7190513

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250